Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.